Author: Institute of Medicine,Board on Health Sciences Policy,Development and Translation Forum on Drug Discovery,Anne B. Claiborne,Steve Olson
Publisher: National Academies Press (November 23, 2012)
Size Fb2: 1813 kb
Size ePub: 1471 kb
Size Djvu: 1305 kb
Other formats: lrf docx lit lrf
Forum on Drug Discovery, Development, and Translation. Board on Health Sciences Policy.
Forum on Drug Discovery, Development, and Translation. Institute of medicine of the national academies.
Institute of Medicine; Board on Health Sciences Policy; Forum on Drug Discovery, Development, and Translation; Steve Olson and Anne B. Claiborne.
Institute of Medicine Board on Health Sciences Policy Roundtable on. .
National Academies Press. to a major alteration in the way that drugs are being developed, with traditionally separate cal and diagnostic companies-now working in close collaboration.
The report is a summary of a forum that brought together members of federal government agencies, the private sector, academia, and advocacy groups to explore options and opportunities in the implementation of Cures Acceleration Network.
Without adequate data from such testing, prescribing drugs appropriately becomes challenging for clinicians treating children, from infancy through adolescence
Without adequate data from such testing, prescribing drugs appropriately becomes challenging for clinicians treating children, from infancy through adolescence. Differences between children and adults in the overall response to medications are due to profound anatomical, physiological, and developmental differences.
Institute of Medicine. Committee on Decreasing the Risk of Alzheimer's-Type Dementia, Mild Cognitive Impairment, and Age-Related Cognitive Impairment.
Topics include: the impact of recent discoveries related to brain protection strategies, reversing cardiac .
Topics include: the impact of recent discoveries related to brain protection strategies, reversing cardiac arrest and death, consciousness, the human experience of cardiac arrest, and transformational experiences of death.
Advances in technologies and knowledge are creating new avenues for research and opportunities for the discovery and clinical development of innovative therapies and diagnostics. However, despite these opportunities, only a small fraction of investigational products are successfully developed into cures and therapies that can be accessed by patients. One response to the ever-widening gap between the number and promise of basic scientific discoveries and the translation of those discoveries into therapies is a renewed emphasis on collaborative approaches among federal agencies, academia, and industry, all directed at the advancement of the drug development enterprise. The newly developed Cures Acceleration Network (CAN)-a part of the National Center for Advancing Translational Sciences (NCATS) within the National Institutes of Health (NIH)-has the potential to catalyze widespread changes in NCATS, NIH, and the drug development ecosystem in general. On June 4-5, 2012, the IOM Forum on Drug Discovery, Development, and Translation held, at the request of NCATS, a workshop-bringing together members of federal government agencies, the private sector, academia, and advocacy groups-to explore options and opportunities in the implementation of CAN. Accelerating the Development of New Drugs and Diagnostics: Maximizing the Impact of the Cures Acceleration Network: Workshop Summary summarizes the workshop.